drugset / Trial / NCT03019653
Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome
Phase 1
Completed
40 enrolled
Mayo Clinic
National Heart, Lung, and Blood Institute (NHLBI) · collabNational Institutes of Health (NIH) · collab
RandomizedCrossoverTriple-blindPrevention
Summary
The purpose of this study is to look at kidney function and hormonal function in patients with a history of heart failure and kidney dysfunction, and to see how the use of a new drug, ANX-042, affects those functions.
Timeline
- Start
- 2017-01
- Primary completion
- 2024-09-13
- Completion
- 2024-09-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ANX-042 | Peptide | 0.003 ug/kg | Other |
| Comparator | ANX-042 | Peptide | 0.006 ug/kg | Other |
| Comparator | ANX-042 | Peptide | 0.01 ug/kg | Other |